Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B cell non-Hodgkin lymphoma

Correction: Invest New Drugs

10.1007/s10637-020-00916-3

The original version of this article unfortunately contained an error. In the Conflict of interest statement, Anne-Marie Quinson is described as declaring no conflict of interest. In fact, as her affiliation shows, she is an employee of Boehringer Ingelheim Pharmaceuticals Inc. The corrected conflict of interest statement is shown below.

Conflict of interest Frank Kroschinsky reports receiving reimbursement for costs of study treatments, documentation, congress fees and travel expenses from Boehringer Ingelheim. Jan Moritz Middeke declares that he has no conflict of interest. Martin Janz declares that he has no conflict of interest. Georg Lenz reports personal fees and/or research support from Amgen, AstraZeneca, BMS, Abbvie, Bayer, Janssen, Novartis, Gilead /Kite, Celgene, Roche, Takeda, Morphosys, ACERTA, AQUINOX, Agios, Verastem, NanoString, and Springer, outside the submitted work. Mathias Witzens-Harig declares that he has no conflict of interest. Reda Bouabdallah declares that he has no conflict of interest. Paul La Rosée reports personal fees from Boehringer Ingelheim (Travel support). Andreas Viardot reports personal fees and non-financial support from Roche, personal fees and non-financial support from Kite/Gilead, nonfinancial support from Abbvie, personal fees from Amgen, outside the submitted work. Gilles Salles reports personal fees from Amgen, BMS, Abbvie, Janssen, Merck, Novartis, Gilead / Kite, Epizyme, Pfizer, Celgene, Roche, Takeda, Autolus, MOrphosys, ACERTA, and Servier, outside the submitted work. Seok Jin Kim declares that he has no conflict of interest. Tae Min Kim declares that he has no conflict of interest. Oliver Ottmann declares that he has no conflict of interest. Joerg Chromik declares that he has no conflict of interest. Anne-Marie Quinson is an employee of Boehringer Ingelheim Pharmaceuticals Inc. Ute vonWangenheim and Ute Burkard are employees of Boehringer Ingelheim. Andreas Berk is an employee of ClinTriCare GmbH & Co. KG, contracted by Boehringer. Norbert Schmitz declares that he has no conflict of interest.